reports
Assured Guaranty Ltd: 1 director
A director at Assured Guaranty Ltd sold/gave away 125,000 shares at 0.000USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Reed’s Reports Fourth Quarter and Full Year 2025 Results; Announces Le...
Reed’s Reports Fourth Quarter and Full Year 2025 Results; Announces Leadership Transition Profitable Growth Initiatives Lead to Sequential Quarterly Improvement Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months and 12 months ended December 31, 2025. Additionally, the Company announced that Neal Cohane has been appointed to serve as in...
Dorchester Minerals, L.P. Announces Settlement Agreement
Dorchester Minerals, L.P. Announces Settlement Agreement DALLAS, March 16, 2026 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) and Dorchester Minerals Operating LP (the “Operating Partnership”) have entered into a settlement and mutual release agreement (the “Settlement Agreement”) with unrelated third parties. The Settlement Agreement resolves ordinary course litigation affecting certain leasehold in Midland County, Texas, which is owned by the Operating Partnership and subject to the Net Profits Interest. The Operating Partnership received proceeds of ...
Reed’s Schedules Fourth Quarter & Full Year 2025 Conference Call for M...
Reed’s Schedules Fourth Quarter & Full Year 2025 Conference Call for March 25 at 8:30 a.m. ET NORWALK, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Wednesday, March 25, 2026, at 8:30 a.m. Eastern time to discuss its financial results for the three and twelve months ended December 31, 2025. The Company’s results will be reported in a press release prior to the call. Reed’s management will host the conference call, fol...
Soleno Therapeutics Announces Retirement of James Mackaness and Appoin...
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year t...
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financia...
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Rev...
Dorchester Minerals, L.P. Announces 2025 Results
Dorchester Minerals, L.P. Announces 2025 Results DALLAS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the year ended December 31, 2025 of $57,352,000 or $1.16 per common unit. A comparison of the Partnership’s consolidated results for the twelve month periods ended December 31, 2025 and 2024 are set forth below: Twelve Months Ended December 31, 2025 2024Operating Revenues$152,832,000 $161,523,000Net Income$57,352,000 $92,449,000Net Income Per Common Unit$1.16 $2.13 The Partnership’s indepen...
Dorchester Minerals, L.P. Announces Appointment of Manager to Board of...
Dorchester Minerals, L.P. Announces Appointment of Manager to Board of Managers DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ: DMLP) announced today Mr. A. Troy Sturrock has been appointed to the board of managers of the general partner of our general partner, as an independent manager and member of the advisory committee effective February 11, 2026. Mr. Sturrock’s appointment fills the vacancy created by the death of C.W. “Bill” Russell. Mr. Sturrock has over 25 years of accounting and financial reporting experience, with a focus on the ...
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financ...
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM East...
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date...
Dorchester Minerals, L.P. Announces Its Fourth Quarter Distribution
Dorchester Minerals, L.P. Announces Its Fourth Quarter Distribution DALLAS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- — Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s fourth quarter 2025 cash distribution. The distribution of $0.755712 per common unit represents activity for the three-month period ended December 31, 2025 and is payable on February 12, 2026 to common unitholders of record as of February 2, 2026. Cash receipts attributable to the Partnership’s Royalty Properties during the fourth quarter totaled approximately $32.2 million. Approximately 62% of these re...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Fu...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million.Preliminary unaudited ...
Soleno Therapeutics Announces Publication of Results from Pivotal Stud...
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Withdraw...
Reed’s, Inc. Announces Appointment of Neal Cohane as Chief Operating O...
Reed’s, Inc. Announces Appointment of Neal Cohane as Chief Operating Officer NORWALK, Conn., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the appointment of Neal Cohane as Chief Operating Officer, effective January 5, 2026. Mr. Cohane brings decades of leadership experience across the beverage industry and a proven track record of building high-performing commercial organizations, scaling national distribution, and driving sustainable gr...
Dorchester Minerals, L.P. Announces the Retirement of Mr. William Case...
Dorchester Minerals, L.P. Announces the Retirement of Mr. William Casey McManemin from the Board of Managers; Appointments of Mr. Robert C. Vaughn as Interim Chairman and Mr. Albert G. Nance III to the Board of Managers DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announces the retirement of Mr. William Casey McManemin from the Board of Managers of Dorchester Minerals Management GP LLC, the general partner of the Partnership’s general partner (the “Board”), effective December 31, 2025. Mr. McManemin previously led the Partnershi...
Reed’s, Inc. Announces Closing of $10 Million Public Offering and Upli...
Reed’s, Inc. Announces Closing of $10 Million Public Offering and Uplisting to NYSE American Stock Exchange NORWALK, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the closing of its previously announced underwritten public offering of 2,500,000 shares of its common stock and warrants to purchase 2,500,000 shares of common stock (collectively, the “Securities”). Each share of common stock and accompanying warrant to purchase one share ...
Reed’s, Inc. Announces Pricing of $10 Million Public Offering and Upli...
Reed’s, Inc. Announces Pricing of $10 Million Public Offering and Uplisting to NYSE American Stock Exchange NORWALK, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock and warrants to purchase 2,500,000 shares of common stock (collectively, the “Securities”). Each share of common stock and accompanying warrant to purchase one share of common stock are be...
Dorchester Minerals Lp: 1 director
A director at Dorchester Minerals Lp bought 5,000 shares at 21.965USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Soleno Therapeutics Announces the Passing of Board Member William G. H...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Health...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A and replay of the presentation will be available in the Investors section on the Company’s we...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.